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Abstract
BACKGROUND—Meningomyelocele (MM) is a common human birth defect. MM is a disorder
of neural development caused by contributions from genes and environmental factors that result in
the neural tube defect and lead to a spectrum of physical and neurocognitive phenotypes.
METHODS—A multi-disciplinary approach has been taken to develop a comprehensive
understanding of MM through collaborative efforts from investigators specializing in genetics,
development, brain imaging, and neurocognitive outcome. Patients have been recruited from five
different sites: Houston and the Texas-Mexico border area; Toronto, Canada; Los Angeles,
California; and Lexington, Kentucky. Genetic risk factors for MM have been assessed by
genotyping and association testing using the transmission disequilibrium test.
RESULTS—A total of 509 affected child/parent trios and 309 affected child/parent duos have
been enrolled to date for genetic association studies. Subsets of the patients have also been
enrolled for studies assessing development, brain imaging, and neurocognitive outcomes. The
study recruited two major ethnic groups with 45.9% Hispanics of Mexican descent and 36.2%
North American Caucasians of European descent. The remaining patients are African American,
South and Central American, Native American and Asian. Studies of this group of patients have
already discovered distinct corpus callosum morphology and neurocognitive deficits that associate
with MM. We have identified maternal MTHFR 667T allele as a risk factor for MM. In addition,
we also found that several genes for glucose transport and metabolism are potential risk factors for
MM.
CONCLUSIONS—The enrolled patient population provides a valuable resource for elucidating
the disease characteristics and mechanisms for MM development.
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INTRODUCTION
One in 33 babies born in the United States has a major birth defect. Neural tube defects
(NTDs) are a group of common birth defects with a congenital malformation of the central
nervous system affecting approximately 6 in 10,000 live births in the United States (Yen et
al., 1992) in 1989 and decreased to 5.4 in 2003–2004 (Boulet et al., 2008). The estimated
spina bifida (SB; a subset of NTDs involving abnormalities of spinal closure below the
region of the head) prevalence was reported at approximately 3.39 per 10,000 live births in
the US during 2003–2004, decreased from 4.89 per 10,000 live births in 1995–1996 before
folic acid fortification of enriched flour products was mandated by United States Food and
Drug Administration (USFDA) (Canfield et al., 2005; Boulet et al., 2008).
NTDs basically result from a failure of the neural tube to close properly during the first
month of pregnancy, a period when the pregnancy most often has not yet been recognized
by the mother. While NTDs broadly include lack of closure anywhere along the neural tube,
the majority of cases can be categorized as either lack of closure in the region of the head
(anencephaly) or lack of closure below the head (spina bifida; also termed “split spine”)
with approximately equal frequencies observed at birth (Botto et al., 1999; Melvin et al.,
2000). Individuals affected with anencephaly die soon after birth. With modern medical
treatment, nearly all babies born with spina bifida (SB) survive. The most common form of
spina bifida is meningomyelocele (MM; lack of closure along the spine affecting the
meninges as well as the neural tissue). Surgical closure must occur within 48 hours of birth
to prevent infection and further damage (Walsh and Adzick, 2003). Many patients require
ventriculo-peritoneal shunting because of the associated hydrocephalus. Depending on level
of spinal defect, the child may never walk or achieve bowel or bladder control. Additionally,
there are learning difficulties, only recently appreciated (Fletcher et al., 1992b, 2002, 2005).
The physical and intellectual handicaps associated with NTDs can range from mild (in a
minority of cases) to severe (in many cases) resulting in morbidity and sometimes premature
mortality for affected individuals as well as a significant societal burden (Iqbal, 2000). An
estimated total annual economic cost of $489 million dollars per year (in 1992 dollars) was
suggested by a year 2000 study (Iqbal, 2000) to provide physical and rehabilitation care for
all SB patients in the US. As the most common severely disabling birth defect in North
America, our knowledge of spina bifida is very fragmented. Extensive research ranging
from large epidemiological studies, creating rodent models, and gene association studies
have been conducted trying to determine the molecular underpinnings leading to formation
of NTDs. Others have studied the neurocognitive function deficits specifically observed in
MM patients in order to understand the core deficits among these patients (Dennis et al.,
1981, 1993; Brandt et al., 1994; Landry et al., 1995; Fletcher et al., 1992a, 1992b, 1996).
MM is a disorder of neural development with contributions by complex gene and
environmental factors interacting to produce the neural tube defect and leading to a spectrum
of physical and neurocognitive phenotypes. Comprehensive understanding of MM requires a
multi-disciplinary approach.
History of project
A collaborative effort from investigators specializing in genetics, development, brain
imaging, and neurocognitive outcome was initiated at our institution [The University of
Texas Medical School at Houston (UTMSH)] in 1997 to set up a Program Project with Dr.
Jack Fletcher as principal investigator. Our main goal was, and continues to be, integration
of knowledge learned by different investigators who are studying the same cohort of MM
affected individuals to aid in prevention and treatment of this birth defect. We seek to
elucidate physical and neural mechanisms underlying the variability in outcomes, and the
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genetic and environmental factors underlying this variability in the phenotype of MM. The
Program Project includes projects with aims to: a) evaluate genetic factors associated with
the physical, neural, and behavioral/cognitive phenotypes; b) characterize the physical,
neural, and cognitive/behavioral phenotypes, c) evaluate core process and functional deficits
across life-span from infancy and middle adulthood, d) provide specific evaluations of the
role of the CNS anomalies of the spine and brain associated with MM to the phenotypes.
One focus of the Program Project is to determine genetic factors involved in MM formation.
Many mouse models provide evidence to support the important role of genes in NTD
development (Harris and Juriloff, 2007). There exists variation of disease prevalence along
ethnic and racial lines (e.g. Irish) having a much higher a priori risk to have a child with
NTD also infers genetic etiology of NTD (Melvin et al., 2000). While there are many clues
from previous studies, the work to define the genetic components causing MM is hampered
by the complex genetic nature of the problem. Closure of the neural tube is an extremely
intricate process requiring the appropriate work of many different genes. We are dealing
with no clear-cut mode of inheritance and few families with more than one affected person.
Fortunately, many affected families are interested in participating in research to try and help
unlock the mystery.
With many new genetic techniques and the completion of the Human Genome Project
providing vast knowledge of new genetic markers, we are using these new tools to examine
genetic markers for associations with risk for MM in our patients. Our approach utilizes
simplex MM families (families with one member affected with an MM) in the genetic
studies using the transmission disequilibrium test (TDT) statistical approach to identify risk
associating genes in concert with effects of environmental influences. To aid in sorting out
the environmental influences affecting the genetic factors, we are obtaining data from two
detailed surveys assessing socio-demographic, epidemiologic and environmental factors.
For the genetic studies, we have chosen to recruit from two major ethnic groups in North
America: Hispanics of Mexican descent and Caucasians of European descent. In North
America, individuals of Hispanic Mexican heritage have the highest risk of having NTD
affected offspring (Canfield et al 1996a, b) prompting our project to select Hispanic
Mexican Americans as one of the two major populations to study other than the Caucasian
Americans of European descent. The Hispanic population is the largest and fastest growing
minority in the U.S. making NTDs in Hispanics a major public health issue. Unfortunately,
genetic studies of Hispanic individuals in North America are more difficult than study of
individuals from other ethnic groups because of the complexity. Many studies have reported
the admixed nature of Mexican Americans in Texas and surrounding border States (Hanis et
al., 1991; Bertoni et al., 2003; Price et al., 2007). Using ethnic specific single nucleotide
polymorphism (SNP) markers, it was found that the major contributing ancestries for
Hispanic Americans in the Southern and Western United States are European and Native
American with a small percentage African ancestry. A higher contribution of African
ancestry for Hispanic Americans in the North and Northeastern United States has been
reported (Bertoni et al., 2003). Defining the ancestral contribution of admixed population
assists in selection of appropriate controls and genetic markers for genetic association
studies. Determining admixture in our Hispanic patients, parents and controls is an
important goal of the study with results reported below.
The following sections describe the properties of the MM patient population in our study
along with a description of our approach to identify the genetic and environmental factors
contributing to the risk of developing MM.
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MATERIALS AND METHODS
Patient recruitment
Patients and their parents were enrolled in the study after obtaining informed consent and
their blood and/or saliva samples were sent to our laboratory for DNA extraction. The
protocol of this study was approved by the Committees for the Protection of Human
Subjects (CPHS) at The University of Texas Medical School at Houston (UTMSH) and
Baylor College of Medicine (BCM). Sites for enrollment of subjects born between 1955 and
2008 (ages 0.4–53 years) and their parents included the Shriners Hospital for Children at
Houston (HOU), Texas; the Shriners Hospital for Children at Los Angeles (LA), California;
the Shriners Hospital for Children at Lexington (LEX), Kentucky; Texas Children’s
Hospital (TCH), Houston, Texas; Hospital for Sick Children TOR), Toronto, Canada; and
individuals referred from Texas not treated at HOU and TCH (OTH). Patients were recruited
by nurses at clinic visits or at support group meetings. Patients with a diagnosis of an
isolated (nonsyndromic) meningomyelocele (MM) at birth were eligible. The baseline
information gathered on each study subject included ethnicity, level of defect, and family
history.
The ethnicity of the affected individual was determined according to: 1) a: statement by
parent that the parent is a member of a specific ethnic group, 2) place of birth of parent and/
or 3) statement that the parent is a descendent of a specific ethnic group. The level of defect
was determined from the medical record and in some cases by review of X-rays. Level of
defect was classified according to the vertebral sites which failed to close resulting in
formation of meningomyelocele (i.e. at or above vertebrae L-1 and at or below vertebrae
L-2). A three-generation family history was obtained along with information regarding any
more distantly related individuals who had any features suggestive of/consistent with an
NTD of any type.
Sample preparation
Blood samples and/or saliva samples were obtained from the patients and both parents when
possible. Genomic DNA from blood cells was extracted using the Puregene DNA extraction
kit (Gentra Systems, Inc.; Minneapolis, MN) and Oragene DNA collection kit (DNA
Genotek, Inc., Ottawa, Ontario, Canada) from saliva. Anonymous control DNAs from 92
Hispanic individuals from the Houston area and 92 Caucasian individuals from the
HD100CAU panel were used as negative controls. Genotyping quality control was
accomplished using DNA samples from 30 CEPH families used in HapMap project. Patient
family DNAs from Toronto, Canada were extracted before sending to our laboratory.
Survey/Questionaire
One goal of our Program Project is to analyze the joint effects of environmental factors and
genetic variants of MM candidate genes in determining the phenotypes of our MM patients
including lesion level, brain dysmorphologies, cognitive function and behavior. We
designed two surveys to collect information on socio-demographic, epidemiologic and
environmental factors including dietary status of our patient families. The environmental
survey questions will be posted on the web link http://www.uh.edu/~sandi/. In addition,
participants were asked to complete a highly detailed nutrition survey designed with
NutritionQuest on the dietary habits. The nutrition survey consists of questions ranging from
general habits, to specific questions about several foods within a variety of different
categories (e.g. beverages, fruits, vegetables, grains, meat and dairy). For each specific food,
participants were asked both frequency and quantity consumed.
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Genetic marker selection
A candidate gene approach was designed for our study with the focus on genes involved in
the folate metabolism/catabolism pathways (Volcik et al. 2000), glucose homeostasis
maintenance (Davidson et al., 2008), and genes known to cause NTDs in small animals
when mutated (Harris and Juriloff, 2007; Volcik et al 2002). A list of genes and genomic
regions known to associate with spina bifida were selected through literature review.
Microsatellite markers and single nucleotide polymorphisms (SNPs) within or near the
genes of interest were obtained from public databases (http://www.ncbi.nlm.nih.gov/SNP/
and http://genome.cse.ucsc.edu/) with SNP heterozygosity present in at least 5% of the
HapMap CEU (Centre d Etude du Polymorphisme Humain UTAH residents with ancestry
from Northern and Western Europe) population. SNPs with potential functional implication
were preferentially selected. The information on the heterozygosities of almost all selected
SNPs for Mexican Americans was not publicly available at the time of SNP selection and
only limited numbers of SNPs are available at present. For follow up evaluation, a SNP
screening density of ~1Kb per SNP is performed for genes associated with significant SNPs
in an initial low density screen.
DNA genotyping
SNP genotyping has been carried out using the SNPlex Genotyping platform (ABI, Foster
City, CA) based on an oligonucleotide ligation/PCR/probe hybridization assay that can
interrogate selected 48 SNPs simultaneously in one reaction. Working DNA stocks of 200
ng were used for each SNPlex reaction. PCR amplification was performed in a 10 ul
reaction volume. The reaction experiments were performed using the manufacturer’s
standard SNPlex protocol with the raw genotyping runs using the ABI 3730xl DNA
analyzer. Data analyses were performed using the GeneMapper v4.0 software and the
genotypes called by the software were examined by at least two investigators before
exporting and compiling for statistical analyses.
Admixture analyses
Genotypes generated on 23 single nucleotide polymorphisms in 12 genes located on 9
different chromosomes are used to determine the proportion of Yoruban African (YRI) vs
CEU ancestry in the Caucasian (N=230) and Hispanic Mexican (N=336) MM patient
populations using the program “Structure” (Pritchard et al., 2000; Falush et al., 2003, 2007).
The 23 SNPs include: rs11761556, rs11763517, rs1188977, rs12406072, rs1286648,
rs1286763, rs1286765, rs1385068, rs1435706, rs1465057, rs17016566, rs2051423,
rs2715553, rs2850760, rs2850763, rs3754219, rs3818569, rs3828942, rs4998557, rs697763,
rs743682, rs7487904 and rs799917. These loci were selected based on an average difference
in minor allele frequencies of 0.3 or higher between the YRI and the CEU populations of the
HapMap. A proportion of YRI and CEU ancestry of each individual samples was computed
with a 5,000 burn-in periods for 10,000 repetitions and data were plotted in relationship to
the YRI and CEU reference clusters.
Statistical Analysis
We chose to use the transmission disequilibrium test (TDT) in GeneHunter2 (Kruglyak et
al., 1996) to test association of genetic markers with risk of MM because 1) almost all of the
MM patient families are small trios, and 2) more then half of our patients are Hispanics of
Mexican descent. An important feature of the TDT is its robustness in studying population
with substructures like the MM patient population we have enrolled (Ewens and Spielman
1995). To fully utilize genotype data from our sample set with a significant number of duos,
we also used the reconstruction combined-TDT (RC-TDT) (Knapp 1999 a and b). To
analyze quantitative phenotypes, we used quantitative-TDT (QTDT; Abecasis et al., 2000).
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In addition to TDT, we also use the genomic control (GC) method (Devlin & Roeder, 1999)
as a secondary method to analyze our data. The GC method uses data sets with no
information on genealogy of the population and corrects for population heterogeneity, poor
choice of controls and cryptic relatedness of cases. A positive finding is concluded when the
allele-wise and genotype-wise testing yields a p-value <0.05 and the goodness-of-fit testing
yields a p-value >0.05. Both Bonferroni correction and Monte Carlo approach were used to
evaluate spurious significance of association due to multiple statistical tests. Interactions of
gene-gene and gene-environment will be examined using a non-parametric, model free
multifactor dimensionality reduction method (Ritchie et al., 2003). Analyses on the
proportion of admixture in our patient subpopulations were performed using the “Structure”
program (Pritchard et al., 2000; Falush et al., 2003, 2007).
RESULTS: CHARACTERISTICS OF PATIENTS IN THE STUDY
Geographic locations
The patients in our study were enrolled from five major sites (Table 1). Approximately 60%
of the patients were recruited in the Houston and Texas border areas, the remaining 40%
were recruited from the LA area (16.8%), the Toronto area (14.9%), and Lexington area
(8.2%). Approximately 69% of our Hispanic patients of Mexican descent were recruited in
the Houston and Texas border areas and 29% from the LA area. Forty percent (125/313) of
our Caucasian patients were recruited in the Houston and Texas border area (HOU, TCH
and OTH), 33% (103/313) from Toronto, 22% (70/313) from LEX and 5% (15/313) from
LA.
Family structure
To date we have recruited 509 trios, 287 mother/child duos, 22 father/child duos and 47
affected individuals in our study to search for genetic factors contributing to MM (Table 1).
The target for the study is to recruit 300 Hispanic trios of Mexican descent and 250 North
American Caucasian trios of European descent. Currently we have recruited 246 Hispanic
Mexican trios and 190 North American Caucasian trios of European descent (Table 2). In
90% of the families recruited for the study, the affected individual is the only affected
person; thus, in the vast majority of our recruited families there is a negative family history
for NTDs. The remaining 10% of our families have reported to have either a close or distant
relative with some form of NTDs and/or NTD-related complication [hydrocephalus, spina
bifida (either MM, meningocele or spina bifida occulta), or anencephaly]. A similar
proportion of families having a history of NTDs was present at each of the five recruiting
sites (data not shown). One family has identical twins both affected with MM and two other
families have fraternal twins, one set with both children affected and the other set discordant
for MM.
Gender
Overall, our patient group has a slightly higher (50.4%) number of female affected patients
than male patients (45.4%) and this trend is observed throughout patients of all ethnic
groups and across all recruiting centers in our study (Table 1). The observed differences
between numbers of female and male MM patients in the project and between sites was not
statistically significantly different (Table 2) (p-value =1.0, χ2 =1.0, degree of freedom =6). A
trend of more female patients among groups of different ethnicities was observed but the
differences, again, were not significant (Table 2) (p-value =0.6, χ2 =4.6, degree of freedom
=6).
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Ethnicity
This cohort of 865 MM patients consists of two major ethnicities: Hispanics of Mexican
descent (45.9%) and North American Caucasians of European descent (non-Hispanic
whites, 36.2%) as seen in Table 2. Patients of other ethnicities include: 4.0% African
American, 2.5% Hispanic non-Mexican, 0.7% Asian/Pacific Islander, 5.3% others (Native
American and others) and 5.3% of unknown ethnicity.
Admixture
We sought to determine how the proportion of admixture differed among the Caucasian MM
patients, the Hispanic Mexican MM patients, and the locally recruited Hispanic controls in
our study. Analyses of the genotypes generated on 23 single nucleotide polymorphisms in
12 genes located on 9 different chromosomes using the program “Structure” showed the
YRI and CEU populations cluster nicely into either the first inferred cluster or the second
inferred cluster respectively while the MM patients were located near the CEU cluster (data
not shown). The proportion of African ancestry for the CEU and the MM Caucasian patients
are very similar (9.2% for CEU and 10.6% for MM Caucasian patients) and slightly higher
among MM Hispanic Mexican patients (13.8%). Similar results were observed when
comparing the Hispanic patients from LA (10.8% YRI ancestry) and the Hispanic patients
from the Houston Texas area (12.1% YRI ancestry). These proportions are not appreciably
different. When similar analyses were subjected to examine MM Hispanic Mexican patients
compared to the Hispanic controls the proportions of YRI ancestry these are also very
similar (12.1% and 14.2% respectively).
Age
In general, our patients were born between 1955 and 2008. Based on the available dates of
birth data we collected, our patients recruited at different sites have median ages between
12.9 to 22.2 years with the range between 0.4–53.0 years. Patients recruited from the TCH
site were younger (median age 12.9 years) and over half of these patients were conceived
after 1992. The median ages for patients recruited are shown in Table 3. The mean ages for
patients recruited through different sites were as follows: HOU (14.9 years), TCH (12.3
years), TOR (21.4 years), LA (19.93), LEX (21.6 years) and OTH (17.3 years). All patients
recruited in the Houston Texas area were younger than 26 years old. The youngest patient
recruited is 0.4 years at TCH while the oldest patient recruited is 53 years old from the
Toronto site.
Lesion Level
Our MM population has been divided by lesion level for purposes of some analyses. These
categories are: 1) failure of closure at L1 and above, and 2) failure of closure at or below L2.
Some of our patients were reported to have the lesion in the sacral region. For these patients,
more refined classification is not available to determine exact involvement from the lower
lumbar to the S2 regions. In our study, male patients were less frequent (9.2%) among the
MM patients with higher lesions (located on or above vertebrae L1) than female patients
(13.1%) (Table 4) while almost evenly distributed (female 30.2%, male 31.2%) in the group
having lesions below vertebrae L1. Since our study includes patients born after folic acid
fortification, this may be a factor causing the difference we have observed between our
study and others. For our subject population, the distribution of defect levels was relatively
similar among patients of all the ethnic backgrounds (Table 4). Approximately 25%
(100/397) Hispanic Mexican and African American and 22% (69/313) Caucasian American
patients have lesions at or above vertebrae L1. Lesions on or below vertebrae L2 were
determined to have occurred in ~68% (270/379) Hispanic Mexican and African American
patients and 59.7% (187/313) Caucasian American patients.
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We found a slightly higher number of female patients (25.9%) with lesions at or above
vertebrae L1 than male patients (20.3%) although this difference was not significantly
different (p=0.071). Lesions at or below vertebrae L2 were observed in 59.9% female
patients and 68.7% male patients respectively (Table 4).
Between 17–27% of MM patients recruited through our five major sites had lesions located
on or above vertebrae L1 (Table 4). The frequency of lesion location did not significantly
differ across four sites (~21–26%) with the exception being the Toronto site at 17.1%.
However, lesion information was not available for approximately 42% of the Toronto
patients indicating that the Toronto data may have been biased. Missing lesion information
accounted for less than 10% for patients recruited through the other four sites
DISCUSSION
To date, we have recruited an MM population including 509 trios and 309 duos. The
majority of our patients are from three areas (Texas, Toronto and LA) where the general
NTD epidemiology and folic acid supplementation knowledge and usage status for the
women of child bearing age have been reported (Hendricks et al., 1999; Canfield et al.,
2005, 2006; de Jong-van den Berg et al., 2005; Goldberg et al., 2006). Our reason for
focusing on recruitment of Hispanics of Mexican descent along the Northern Mexican
border with Texas and California was for several reasons: proximity to our location; this
population is more likely to be affected with an NTD (Hendricks et al. 1999); and because
there was some evidence to support more genetic homogeneity among this group of
Hispanic individuals than other Hispanic individuals throughout the US (Hanis et al., 1991).
We chose North American Caucasians of European descent because they have the second
highest incidence of NTDs in the US and represent the majority of the population.
For purposes of our genetics studies, we have estimated the power of using TDT to detect
risk allele (γ1=2) with a power of nearly 1 for gene frequency ≥0.1 using a trio population of
550 when the risk allele acts in either a multiplicative, additive or dominant manner
(α=0.01). A slight decrease in power to 0.9–0.97 was estimated when the number of trios
was reduced to 300. The current MM population we have recruited should provide sufficient
power for detecting MM risk alleles with gene frequency higher than 0.1. In a recessive
model, we estimated 550 families provide a power of 0.98 for a gene frequency of 0.5
(α=0.01) but the power deteriorated quickly to 0.1 with a gene frequency of 0.1. A much
larger number of families will be needed if MM inherited in a recessive manner. In addition,
larger number of families will be needed to examine genetic factors with relative risk less
than 2. The current number of trios and duos already provided us sufficient statistical power
for TDT analyses and led us to further investigate other SNPs within the breast cancer gene
1 (BRCA1) (King et al., 2007), leptin receptor (LEPR), solute carriers type 2 A gene 1
(SLC2A1 alias GLUT1), and hexokinase 1 gene (HK1) that showed association with MM
risk in our patient group (Davidson et al., 2008). The MM population in our study has also
been reported to show associations with methylene tetrahydrofolate reductase variant
(MTHFR 677T) and microsatellite markers near the pairbox (PAX1, 7 and 8) genes (Volcik
et al., 2000, 2002). Recruitment is continuing with the goal to obtain at least 300 Hispanic
trios of Mexican descent and 250 North American Caucasian trios of European descent to
improve the power of analyzing risk factors for individual ethnic groups and for sub-
phenotypes (i.e. brain dysmorphologies, neurocognitive deficits) analysis.
In 2006, the daily consumption of a supplement with folic acid (FA) among Texas women
of child bearing age was determined to be low (40% non-Hispanic white, 24% Hispanic)
(Canfield et al 2006) especially for residents along the Mexican border (20.8%). The finding
for usage of supplements containing folic acid among women in the Toronto area between
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1998 and 2002 was similar (47.2% white, 17.9% Hispanic, respectively) and FA usage in
relevant period between 1988 and 1994 was 15–20% (de Jong-van den Berg et al, 2005). We
do not anticipate the proportion of folate resistant MM cases in our study patients to
represent an overwhelming majority considering the low FA usage among Hispanics,
especially along the Texas-Mexico border (Hendricks et al., 1999). The US Public Health
Service recommended women of childbearing age to consume 400ug FA daily starting in
1992 and the recommendation was quickly endorsed by the Institute of Medicine, American
Academy of Pediatrics, and American College of Preventive Medicine. A mandate for food
fortification with FA was made starting 1998 by the US Food and Drug Administration
(USFDA). These recommendations and mandate need to be taken into account when
analyzing data generated on our patient population. Patients in our study were born between
1955 and 2008. Over half of the patients recruited from the TCH site were conceived after
1992. Half or more of the patients recruited through different sites (HOU, TOR, LA, LEX
and OTH) were born before 1992. Therefore, we anticipate half or more of the patients in
our study should not be affected by the USPHS recommendation on folic acid. The impact
of folic acid supplementation among patients 16 years and older should be even lower and,
thus, among these patients we anticipate having a larger proportion who potentially have
MM due to lack of folic acid. We are collecting information in two surveys to help us to
delineate the effect of the mandated folic acid fortification by USFDA on our study.
We have shown by admixture analysis that our two patients groups, Hispanics of Mexican
descent and North American Caucasians of European descent, are appropriately matched
genetically with the controls groups we have recruited or obtained commercially. We were
especially cognizant of the problems faced regarding genetic studies of individuals whose
ethnicity is labeled as “Hispanic”. Through our admixture studies we have shown that our
Hispanic Mexican sample including patients recruited in the areas of Houston, Texas, the
Texas-Mexico border, and Los Angeles, California, are genetically the same with respect to
their CEU and YRI ancestries. Genotypes for the SNPs we tested are not publicly available
for Native American as for the CEU and YRI. We can, therefore, compare genotyping
results from our patient sample with our recruited control sample with confidence that the
comparison is valid. The similarity in contributions of European and African ancestry to
Hispanics Mexican in Texas and LA has been reported previously (Price et al., 2007).
Anencephaly has been documented in multiple studies to be 2 to 3 times more common
among females than males but other NTDs including spina bifida showed equal prevalence
between both genders in studies published between 1989 and1991 (Canfield et al., 1996a, b).
A study of SB patients in California between 1983 and1987 reported more male patients
among a group having isolated high open defects and fewer male patients among the group
including all closed defects (Shaw et al., 1994). In our study, female patients are more
frequent among the MM patients with lesions located on or above vertebrae L1 while almost
evenly distributed in the group having lesions below vertebrae L1. Our study includes
patients born after the USFDA mandated folic acid fortification. Whether folic acid plays a
role in the gender differences we have observed between our study and the previous study is
not known. A difference in lesion definition between our study and the previous study could
also be the reason for observed differences.
We are now gathering data regarding environmental factors that may be important in
susceptibility to the formation of MM as well as variation in the MM phenotype. We are
surveying our population for socio-demographic, epidemiologic and environmental factors
following up on previously identified factors that have been implicated as important. We are
gathering data on socioeconomic status, maternal and paternal ages and occupations,
parental birthplaces and maternal reproductive history (gravidity, parity, spontaneous
abortions, birth order) including place of conception. Additionally, we are gathering
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environmental data including maternal diet and vitamin use (folate and other
micronutrients), maternal glucose status (diabetes/epilepsy), maternal exposure to
hyperthermia (illness/hot tubs), maternal medication use (epilepsy, other illnesses) and
maternal use of recreational substances (alcohol, tobacco and illicit drugs). As noted above,
we are making efforts to account for folate status of the mothers dependent on year of the
patient’s birth regarding the recommendations for folate usage followed by USFDA
mandated folic acid fortification of enriched flour. By performing gene-environment
analyses utilizing the data gathered from our surveys, we should be able to make more
progress on both susceptibility and phenotypic variability in MM.
In addition, multiple neurocognitive functioning and brain imaging studies have been
performed in some of the study population (Barnes et al.2006; Burmeister et al.2005; Dennis
et al., 2001, 2002a, b, 2004a, b, 2005a, b, c, 2008; Edelstein et al., 2004; Fletcher et al.,
2002,2005; Hetherington et al., 2006; Huber-Okrainec et al., 2002,.2005; Lomax-Bream et
al., 2007) making it possible to study the effect of genetics and the environment on
neuroembryogenesis resulting in CNS dysmorphologies and subsequent neurocognitve
deficits. From the study population, it was identified that over 50% of children with MM
have part of both ends of the corpus callosum missing, a finding consistent with learning and
behavioral deficits (Dennis et al., 2004; Flectcher et al., 2005). We plan to utilize the
detailed phenotyping obtained in other Projects of the Program Project to make correlations
with the genetic variants.
In conclusion, the MM patient population in our study has reached a sufficient size to
evaluate significance of risk alleles to MM development using standard and reconstruction-
combined TDT. Over 50% of the enrolled patients trios are Hispanics of Mexican descent, a
group known to have a higher incidence of MM. In addition to MM lesion level, other
members of the Program Project are actively pursuing MM disease phenotypes including
brain dysmorphology and neurocognitive deficits to expand our understanding of the
diseases. Correlation of genetic and environmental factors to the newly delineated disease
phenotypes will help us elucidate the physical and neural mechanism for MM outcomes.
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